InsidersTradesSigma
Follow the ImmunityBio, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, ImmunityBio, Inc. has published 69 reports. Market capitalisation: €8bn. The latest transaction was disclosed on 6 July 2026 (Levée d'options). Among the most active insiders: Adcock Richard. The full history is openly available.
69
Insider Decl.
n/a
Thresholds
€91,211
4 ops.
Buy Volume
€4m
9 ops.
Sell Volume
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 July 2026
Declarations69 total
55,979 shares@ US$2.980.0017% mcap6.8% of flowCommon StockSEC:0001529371-26-000008:0
131,210 shares@ US$9.50340.013% mcap50.6% of flowCommon StockSEC:0001529371-26-000008:1
35,064 shares@ US$2.980.0011% mcap4.4% of flowCommon StockSEC:0001849739-26-000014:0
124,414 shares@ US$2.990.0038% mcap15.8% of flowCommon StockSEC:0001849739-26-000014:1
159,478 shares@ US$9.02360.015% mcap61.2% of flowCommon StockSEC:0001849739-26-000014:2
131,210 shares@ US$9.200.013% mcap100.0% of flowCommonSEC144:0001950047-26-006831
159,478 shares@ US$8.7550.017% mcap62.5% of flowCommonSEC144:0001950047-26-006714
1,000 shares@ US$8.770.0001% mcap0.4% of flowCommonSEC144:0001950047-26-006655
95,722 shares@ US$8.710.0098% mcap37.2% of flowCommonSEC144:0001950047-26-006608
25,000 sharesCommon StockSEC:0001647994-26-000011:0
268,033 shares@ US$10.9930.035% mcap59.0% of flowCOMMONSEC144:0001949846-26-000345
4,606,596 shares@ US$5.4275.1% of flowCommon StockSEC:0001189020-26-000008:0
75,000 shares@ US$12.01050.0091% mcap25.9% of flowCommon StockSEC:0001647994-26-000006:0
40,650 shares0Common StockSEC:0001848899-26-000005:0
4,065 shares0Common StockSEC:0001200637-26-000004:0
114,329 shares0Common StockSEC:0001189020-26-000006:0
25,000 shares@ US$2.980.0008% mcap16.5% of flowCommon StockSEC:0001849739-26-000004:0
77,560 shares@ US$8.7049.5% of flowCommon StockSEC:0001830328-26-000005:1
10,000 shares@ US$9.254.4% of flowCommon StockSEC:0001647994-26-000004:0
152,439 shares0Common StockSEC:0001830328-26-000005:0
82,236 shares0Common StockSEC:0001848899-26-000003:0
274,122 shares0Common StockSEC:0001830328-26-000003:0
5,482 shares0Common StockSEC:0001200637-26-000002:0
274,122 shares0Common StockSEC:0001189020-26-000003:0
76,967 shares@ US$6.540.0052% mcap14.6% of flowCommon StockSEC:0001647994-26-000002:0
25 of 69 declarations
关于 ImmunityBio, Inc.
ImmunityBio, Inc. (NASDAQ: IBRX) 是一家在美国纳斯达克市场上市的美国生物技术公司，专注于癌症和特定传染病应用的新一代免疫疗法。该公司由 Patrick Soon-Shiong 于 2014 年创立，他继续担任执行主席，并且是 Nant 关联的更广泛的医疗保健和生命科学生态系统的一部分。其公司和运营足迹以美国为中心，而其开发和商业化战略的国际范围日益扩大。([immunitybio.com](https://immunitybio.com/about/?utm_source=openai)) ImmunityBio 的商业模式围绕平台方法构建：激活和恢复患者的免疫系统，以产生更持久的抗肿瘤反应。其主要资产是 ANKTIVA® (nogapendekin alfa inbakicept)，一种 IL-15 超激动剂/免疫疗法，已在美国获批用于卡介苗 (BCG) 无反应的非肌层浸润性膀胱癌。其产品线还包括 ANKTIVA 与 BCG 的联合用药、非小细胞肺癌 (NSCLC) 项目、针对治疗相关淋巴细胞减少症的方法，以及该公司更广泛的“癌症生物盾”平台下的其他细胞和载体免疫疗法资产。([ir.immunitybio.com](https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-continued-execution-and-sales-momentum-113?utm_source=openai)) 从竞争角度来看，ImmunityBio 在高度竞争的肿瘤免疫疗法领域运营，其差异化取决于临床证据、监管执行和有效商业化的能力。它尚未成为一家大型盈利制药公司，并且仍然面临典型的生物技术风险：试验成功、适应症扩展、报销和规模化执行。尽管如此，它已经拥有上市产品，这使其与许多尚未盈利的生物技术同行区分开来。最近披露的信息表明 ANKTIVA 销售加速，在美国 J 代码永久生效后，产品收入和单位销量显著增长，表明商业吸引力正在形成。([immunitybio.com](https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/?utm_source=openai)) 最近的新闻头条强化了从开发阶段生物技术公司向商业化和多司法管辖区增长故事的转变。在 2025 年和 2026 年初，该公司报告了更强的收入势头、额外的 FDA 相关进展、淋巴细胞减少症的扩大准入授权，以及沙特 FDA 批准 ANKTIVA 用于标准疗法失败后的转移性 NSCLC。ImmunityBio 还宣布与百济神州/BeOne Medicines 达成合作协议，以支持一项确证性 NSCLC 3 期试验。与此同时，该公司筹集了额外资本并调整了资产负债表，强调了为临床开发和商业化扩张提供资金的持续需求。([ir.immunitybio.com](https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-continued-execution-and-sales-momentum-113?utm_source=openai)) 对于投资者而言，ImmunityBio 仍然是一个高回报但高风险的生物技术公司：其上行空间取决于 ANKTIVA 扩展到多种适应症，而主要风险是临床结果、监管挫折和商业化执行。
